Q-omics provides the consensus-scored CD300LD profile across patient tissues and cancer cell-line models. CD300LD expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CD300LD is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, CD300LD RNA expression shows 6,737 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, COAD, and STAD as cancer lineages where CD300LD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD300LD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD300LD survival associations across molecular data types. CD300LD RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD300LD RNA expression–survival associations across cancer types. High CD300LD expression shows unfavorable associations in DLBC, ACC, UCS, LUSC, OV and TGCT. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for CD300LD RNA expression.
This table summarizes CD300LD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CD300LD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD300LD shows lower tumor expression in LUSC and KICH and higher tumor expression in COAD and KIRC. The COAD box plot shows higher CD300LD RNA expression in tumor versus normal tissue (log2 FC = +0.198, t-test p < 0.001).
This table shows molecular features associated with CD300LD in patient tissues and cancer cell lines. In patient samples, CD300LD shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CD300LD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
